Dr. Reddy’s Laboratories (RDY) Announces Rollout of Injectable Semaglutide Under Brand Name Obeda®

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy According to Hedge Funds. On March 21, the company announced the rollout of its injectable semaglutide under the brand name Obeda®. This demonstrates a critical step in the expansion of access to advanced GLP‑1 receptor agonist–based therapy for managing type 2 diabetes in India.

Dr. Reddy’s Laboratories (RDY) Announces Rollout of Injectable Semaglutide Under Brand Name Obeda®

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is the first Indian company to get the DCGI (Drugs Controller General of India) approval for generic semaglutide.

Dr. Reddy’s Laboratories Limited (NYSE:RDY), while quoting the ICMR‑INDIAB study, noted that India has one of the world’s largest diabetes burdens, as more than 101 million adults live with this condition. Semaglutide, which is a GLP‑1 receptor agonist, can improve glycaemic control and help with weight management if used as part of the comprehensive treatment plan. Given that API development, manufacturing, and formulation development occur in-house, Obeda® demonstrates Dr. Reddy’s Laboratories Limited (NYSE:RDY)’s strength in complex product development and peptide science.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) operates as a pharmaceutical company.

While we acknowledge the risk and potential of RDY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RDY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.